PRNewswire

LOS ANGELES, May 31, 2024 /PRNewswire/ -- ooBlue is excited to announce its official launch, introducing a pioneering AI-powered product recommendation search engine designed to transform the online shopping experience. This innovative tool leverages cutting-edge technology to provide users with data-driven insights, enabling smarter, more informed purchasing decisions across a variety of product categories.

ooBlue's platform is built around a powerful artificial... (continue reading...)

Dave Asprey's Brain Upgrade Facility Bolsters Leading Neurofeedback Program with Ketamine and Newly Appointed Medical Director

KENMORE, Wash., May 31, 2024 /PRNewswire/ -- 40 Years of Zen, the world's most exclusive five-day master program and retreat for upgrading the brain located in Kenmore, Washington, today announced it will expand its brain training and neuroscience program to include Psychedelic-Assisted Neurofeedback™ with Ketamine, furthering its mission to... (continue reading...)

PITTSBURGH, May 31, 2024 /PRNewswire/ -- "I wanted to create a product to ease the task of cleaning in between toes while showering/bathing," said an inventor, from Pennsylvania, "so I invented the TOE JAMMIN'. My design enables you to reach your toes without bending over, which increases safety by reducing the risk of slips in the shower. It also could help to avoid fungi and infection."

... (continue reading...)

VANCOUVER, BC, May 31, 2024 /PRNewswire/ - Gold Royalty Corp. ("Gold Royalty" or the "Company") (NYSE American: GROY) is pleased to announce the closing of its previously announced public offering (the "Offering") of units of the Company (the "Units"). Pursuant to the Offering, the Company issued, on a bought deal basis, 20,058,300 Units, including 2,616,300 Units pursuant to the full exercise of the over-allotment option, at a price of US$1.72 per Unit for aggregate... (continue reading...)

LAFAYETTE, Calif., May 31, 2024 /PRNewswire/ -- The Alexander Shulgin Research Institute (ASRI) has unveiled a groundbreaking discovery in the journal Molecular Pharmacology: the first bifunctional compound that acts as both a 5-HT2A receptor antagonist and a voltage-gated sodium channel blocker. This novel molecule, known as XOB, could revolutionize the treatment landscape for bipolar disorder.

... (continue reading...)